Skip to main content

Table 3 Efficacy and safety outcomes in patients who were enrolled in the first month after ACS compared to those who were enrolled from the second to the sixth months after ACS

From: Insights from Egyptian ticagrelor study in patients who presented with acute coronary syndrome (ETS in ACS)

  First month Second to sixth months P value
Percentage 45.8 54.2  
Composite primary endpoints (%) 2.5 1.8 0.548
Secondary efficacy endpoints (%) 10.8 7.6 0.168
Cardiovascular death (%) 0.7 0.9 0.802
Myocardial infarction (%) 0.7 1.5 0.360
Stroke (%) 2.5 0.6 0.051
Hospitalization for UA (%) 7.9 6.4 0.458
Urgent revascularization (%) 4.3 3.9 0.786
TIMI major bleeding (%) 1.1 1.5 0.641
TIMI minor bleeding (%) 13.7 11.5 0.406
Intracranial hemorrhage (%) 0.4 0.3 0.899
Dyspnea (%) 11.5 9.4 0.394
Bradycardia (%) 4 3.6 0.831